- Home
- GLMD vs HSCS Comparison
GLMD vs HSCS Comparison
Compare GLMD & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- HSCS
- Stock Information
- Founded
- GLMD 2000
- HSCS 2007
- Country
- GLMD Israel
- HSCS United States
- Employees
- GLMD N/A
- HSCS N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- GLMD Health Care
- HSCS Health Care
- Exchange
- GLMD Nasdaq
- HSCS Nasdaq
- Market Cap
- GLMD 4.5M
- HSCS 3.8M
- IPO Year
- GLMD 2014
- HSCS 2022
- Fundamental
- Price
- GLMD $2.70
- HSCS $3.69
- Analyst Decision
- GLMD
- HSCS Strong Buy
- Analyst Count
- GLMD 0
- HSCS 2
- Target Price
- GLMD N/A
- HSCS $13.50
- AVG Volume (30 Days)
- GLMD 21.6K
- HSCS 19.2K
- Earning Date
- GLMD 04-03-2025
- HSCS 03-13-2025
- Dividend Yield
- GLMD N/A
- HSCS N/A
- EPS Growth
- GLMD N/A
- HSCS N/A
- EPS
- GLMD N/A
- HSCS N/A
- Revenue
- GLMD N/A
- HSCS $14,700.00
- Revenue This Year
- GLMD N/A
- HSCS $174.19
- Revenue Next Year
- GLMD N/A
- HSCS $4,100.00
- P/E Ratio
- GLMD N/A
- HSCS N/A
- Revenue Growth
- GLMD N/A
- HSCS 151.28
- 52 Week Low
- GLMD $2.24
- HSCS $2.36
- 52 Week High
- GLMD $23.80
- HSCS $18.50
- Technical
- Relative Strength Index (RSI)
- GLMD 49.41
- HSCS 51.97
- Support Level
- GLMD $2.24
- HSCS $3.70
- Resistance Level
- GLMD $2.72
- HSCS $4.10
- Average True Range (ATR)
- GLMD 0.20
- HSCS 0.30
- MACD
- GLMD 0.02
- HSCS 0.03
- Stochastic Oscillator
- GLMD 71.47
- HSCS 59.00
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.